Cidara Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio230.623.082.311.717.28
P/B Ratio1.80-8.75-3.753.938.20
Price/Tangible Book1.803.938.20
Enterprise Value Ratios
EV/Revenue133.801.180.121.104.28
Profitability & Returns
Return on Equity (ROE)-2.20%-6.09%-2.63%-2.97%
Return on Assets (ROA)-0.40%-0.30%-0.22%-0.39%-0.69%
Return on Invested Capital (ROIC)-0.70%-2.04%-1.17%-1.32%
Return on Capital Employed (ROCE)-0.55%69.74%-3.60%-1.02%-3.29%
Leverage & Solvency Ratios
Debt/Equity0.02-0.59-0.080.230.74
Liquidity Ratios
Current Ratio4.250.901.092.111.48
Quick Ratio3.870.740.931.911.22
Efficiency Ratios
Asset Turnover0.010.410.380.730.19
Yield & Distribution Ratios
Earnings Yield-0.58%-0.32%-0.62%-0.50%-0.82%
FCF Yield-0.60%-0.32%-0.53%-0.30%-0.62%
Buyback Yield-0.45%-0.25%-0.33%-0.26%-0.39%